V Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

V Wealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-50	Closed	-$6K	–	698
2017 Q2	$6K	Buy	+50	New	+$6.02K	﹤0.01%	642

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

V Wealth Advisors's VRTX Position: Q3 2017 in Review

V Wealth Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q3 2017, closing a stake of 50 shares — an estimated $6K sold.

V Wealth Advisors first reported a position in VRTX in Q2 2017 and held it in 1 quarter. The position peaked at $6K in Q2 2017. 611 funds tracked by Wall St. Rank hold VRTX as of Q3 2017.

V Wealth Advisors reported no remaining Vertex Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
V Wealth Advisors sold 50 Vertex Pharmaceuticals shares in Q3 2017, an estimated $6K.
V Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q2 2017 and held it in 1 quarter.
V Wealth Advisors's Vertex Pharmaceuticals position peaked at $6K in Q2 2017.
611 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2017.

Based on V Wealth Advisors's 13F filing for Q3 2017, filed 12 Oct 2017.